What it's for (Indications)
- Aminophylline, marketed under various brand names including Amphiline, is a methylxanthine derivative primarily indicated for the treatment of reversible bronchospasm associated with asthma and chronic obstructive pulmonary disease (COPD).
- It acts as a bronchodilator to alleviate symptoms such as wheezing, shortness of breath, and chest tightness.
- Due to its narrow therapeutic index and potential for significant adverse effects, aminophylline is often reserved for patients who have not responded adequately to other first-line bronchodilators, or as an adjunctive therapy.
- Its use requires careful patient selection and diligent monitoring to optimize efficacy while minimizing risks.
- The clinical application of aminophylline has seen a decline with the advent of safer and more targeted bronchodilators, but it remains a viable option in specific clinical scenarios, particularly in acute exacerbations when administered intravenously.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of aminophylline is highly individualized and complex, necessitating therapeutic drug monitoring (TDM) due to its narrow therapeutic index. It can be administered orally or intravenously. For intravenous administration in acute bronchospasm, a loading dose is typically given over 20-30 minutes, followed by a continuous maintenance infusion. The loading dose is calculated based on ideal body weight and assumes the patient has not received recent xanthine therapy. Maintenance doses vary significantly based on patient age, smoking status, concurrent medications, and hepatic or renal function. For example, adults who are non-smokers typically receive lower maintenance doses compared to smokers or those with certain drug interactions. Oral dosing for chronic management also requires careful titration and TDM to maintain serum concentrations within the therapeutic range of 10-20 mcg/mL. Pediatric dosing is also weight-based and requires even more stringent monitoring. Regular assessment of serum aminophylline levels is paramount to prevent sub-therapeutic concentrations, which lead to treatment failure, or supra-therapeutic levels, which significantly increase the risk of toxicity. |
Safety & Warnings
Common Side Effects
- Aminophylline possesses a narrow therapeutic index, meaning the difference between therapeutic and toxic doses is small, leading to a high incidence of adverse effects, even within the recommended serum concentration range (10-20 mcg/mL).
- Common side effects, often dose-dependent, include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea.
- Central nervous system effects are also prevalent and may manifest as headache, insomnia, nervousness, irritability, restlessness, and tremors.
- More serious and potentially life-threatening adverse events, particularly at higher serum concentrations (>20 mcg/mL), include cardiac arrhythmias (e.
- g.
- , sinus tachycardia, ventricular arrhythmias, palpitations), and seizures, which can occur suddenly without prior warning signs.
- Other less common but significant side effects include hypotension, circulatory failure, and respiratory arrest.
- The elderly, patients with underlying cardiac disease, or those with hepatic impairment are particularly susceptible to severe adverse reactions.
- Prompt recognition and management of these side effects, often involving cessation or dose reduction and serum level assessment, are crucial.
Serious Warnings
- Black Box Warning: Aminophylline does not carry a formal Black Box Warning from the U.S. Food and Drug Administration (FDA). However, due to its narrow therapeutic index and the significant risk of serious adverse events, the following 'Serious Warnings' should be considered with the highest degree of caution: **Serious Warnings: Risk of Life-Threatening Toxicity and Need for Therapeutic Drug Monitoring** Aminophylline has a narrow therapeutic range, and systemic toxicity can occur even at serum concentrations considered within the therapeutic range (10-20 mcg/mL). Severe and potentially fatal adverse reactions, including cardiac arrhythmias (e.g., ventricular fibrillation, supraventricular tachycardia) and generalized tonic-clonic seizures, have been reported. These severe events may occur without prior warning symptoms, such as nausea or headache, particularly in patients with predisposing factors or those with rapid increases in serum levels. Factors that can increase the risk of toxicity include concomitant illnesses (e.g., fever, sepsis, viral infections, liver dysfunction, congestive heart failure), age (elderly and neonates are more vulnerable), and concurrent administration of drugs that inhibit aminophylline metabolism (e.g., cimetidine, erythromycin, quinolones). Therefore, careful individualization of dosage and strict adherence to therapeutic drug monitoring (TDM) protocols are absolutely essential. Regular measurement of serum aminophylline concentrations is critical to ensure patients receive an effective dose while minimizing the risk of life-threatening toxicity. Any signs of toxicity necessitate immediate discontinuation or dose reduction and prompt medical intervention.
- Due to its narrow therapeutic index, aminophylline requires careful monitoring and dose adjustment to avoid serious toxicity.
- Patients with pre-existing cardiac disease, especially those with coronary artery disease, angina pectoris, or arrhythmias, should use aminophylline with extreme caution, as it can exacerbate these conditions.
- Caution is also advised in patients with severe hypertension, hyperthyroidism, peptic ulcer disease, or glaucoma, as aminophylline can worsen these conditions.
- Liver and renal impairment significantly alter aminophylline clearance, necessitating reduced dosages and more frequent serum level monitoring.
- Fever, viral illnesses, and concurrent use of certain medications (e.
- g.
- , cimetidine, erythromycin, oral contraceptives, propranolol) can decrease aminophylline clearance, leading to increased serum concentrations and toxicity.
- Conversely, medications like phenobarbital, phenytoin, and rifampin, as well as smoking, can increase clearance, potentially rendering therapeutic doses ineffective.
- Pregnant and breastfeeding women should use aminophylline only if clearly needed, with careful consideration of potential risks to the fetus or infant.
- Elderly patients may have decreased clearance and increased susceptibility to adverse effects, requiring lower initial doses and close monitoring.
How it Works (Mechanism of Action)
Aminophylline is a non-selective phosphodiesterase (PDE) inhibitor belonging to the methylxanthine class. Its primary mechanism of action involves the inhibition of cyclic nucleotide phosphodiesterase enzymes, particularly PDE3 and PDE4. This inhibition leads to an accumulation of intracellular cyclic adenosine monophosphate (cAMP) in smooth muscle cells of the bronchi and pulmonary vasculature. Elevated cAMP levels activate protein kinase A, which subsequently phosphorylates various proteins, resulting in the relaxation of bronchial smooth muscle and bronchodilation. In addition to PDE inhibition, aminophylline also acts as an antagonist at adenosine receptors. Adenosine is known to induce bronchoconstriction and histamine release, so its antagonism contributes to the bronchodilatory and anti-inflammatory effects of aminophylline. Other proposed mechanisms include modulation of calcium flux, enhancement of diaphragmatic contractility, and anti-inflammatory effects through various cellular pathways, though these are considered secondary to its primary actions as a PDE inhibitor and adenosine antagonist.